FDA Grants Fast Track Designation to Nuvectis Pharma’s NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis”…
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis”…
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis”…
60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing…
60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing…
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody…
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody…
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
NEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
NEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining…
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining…
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the…
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the…
Funding supports advancement of samuraciclib, an oral CDK7 inhibitor, in combination with endocrine therapy for…
Funding supports advancement of samuraciclib, an oral CDK7 inhibitor, in combination with endocrine therapy for…
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH…
In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH…